The Mayo Clinic Platform Accelerate programme has selected 18 promising health tech startups for its latest AI-focused cohort, providing them with mentorship, clinical validation opportunities, data access, and strategic guidance from Mayo Clinic experts. The cohort features companies developing AI solutions across diagnostics, precision medicine, remote monitoring, clinical decision support, and operational efficiency aiming to fast-track clinically impactful innovations from concept to real-world deployment.
Glimpse:
Announced on January 28, 2026, the 2026 cohort includes startups working on AI for early disease detection (cancer, neurological disorders), predictive analytics for hospital operations, ambient documentation tools, personalised treatment planning, and digital therapeutics. Over the 12-month programme, participants gain access to Mayo Clinic’s de-identified datasets, clinical validation pathways, regulatory expertise, and potential pilot opportunities within Mayo’s network. The initiative continues Mayo Clinic Platform’s mission to bridge the gap between innovative health tech and clinical practice.
The Mayo Clinic Platform Accelerate programme has announced its newest cohort of 18 health tech startups, each leveraging artificial intelligence to address critical challenges in diagnostics, treatment, care delivery, and healthcare operations. The 2026 cohort was unveiled on January 28, 2026, following a highly competitive selection process that attracted hundreds of applications from around the world.
The selected companies represent a diverse range of AI applications, including:
- Early detection and risk stratification for cancer, Alzheimer’s, and cardiovascular disease using multimodal imaging and clinical data
- Predictive models for hospital resource utilisation, readmission risk, and sepsis onset
- Ambient AI tools for real-time clinical documentation and workflow optimisation
- Personalised treatment recommendation engines for oncology and rare diseases
- Digital therapeutics and remote monitoring solutions for chronic conditions
Over the 12-month programme, each startup will receive:
- Access to de-identified Mayo Clinic datasets for model training and validation
- Mentorship from Mayo Clinic clinicians, researchers, and data scientists
- Guidance on regulatory pathways (FDA, CDSCO equivalents) and clinical trial design
- Opportunities for pilot deployments within Mayo Clinic’s integrated care network
- Strategic introductions to potential investors, partners, and payers
The cohort will also benefit from Mayo Clinic Platform’s unique “sandbox” environment, which allows secure testing of AI solutions against real-world clinical workflows while maintaining strict privacy and ethical standards.
Dr. [Mayo Clinic Platform Lead] said: “These 18 startups represent the cutting edge of AI in healthcare. By giving them direct access to Mayo Clinic’s clinical expertise, data, and validation pathways, we’re helping them move faster from promising technology to proven solutions that can improve patient care at scale here in the U.S. and globally.”
The Mayo Clinic Platform Accelerate programme, now in its fourth year, has already supported over 50 startups, many of which have gone on to secure FDA clearances, major partnerships, additional funding, and real-world clinical deployments. This year’s cohort reflects the programme’s increasing focus on AI that is clinically rigorous, ethically sound, and practically deployable in diverse healthcare settings.
“AI has enormous potential, but only when it is rigorously validated in real clinical environments. Through Accelerate, we’re giving these innovators the clinical grounding they need to create tools that truly move the needle on patient outcomes.”
By
HB Team
Related News
